BloodPressureHeartMeds.Org

Renal research consortia receives two grants for translational research from DKF

July 14, 2017

"It is a precision approach that is designed to avoid non-targeted cells, increasing antitumor activity in preclinical models and potentially reducing the toxic effects of traditional chemotherapy," says Dr. Von Hoff. Researchers are studying the drug to evaluate its safety and tolerability and identify the maximum tolerated dose.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare was the first to offer patient access to ASG-5ME. Researchers hope to enroll up to 50 patients in clinical trials of the drug in multiple centers across the U.S.

The drug was co-developed by Seattle Genetics, Inc. of Bothell, Wash. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc.

More than 36,000 people are expected to die from pancreatic cancer in 2010, according to the American Cancer Society. Most patients with advanced pancreatic cancer die within one year of diagnosis.

SOURCE Scottsdale Healthcare